Stathmin, interacting with Nf-κB, promotes tumor growth and predicts poor prognosis of pancreatic cancer

Current Molecular Medicine

Volumn 14, Issue 3, 2014, Pages 328-339

  Lu, Y ^a,b,c   Liu, C ^a,c   Cheng, H ^a,c   Xu, Y ^a,b,c   Jiang, J ^a,b,c   Xu, J ^a,b,c   Long, J ^a,b,c   Liu, L ^a,b,c   Yu, X ^a,b,c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Nf B; Pancreatic cancer; Prognosis; Stathmin; Tumor growth

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STATHMIN; PROTEIN BINDING;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MOUSE; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PANCREAS CANCER; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; CELL SURVIVAL; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NF-KAPPA B; PANCREATIC NEOPLASMS; PROTEIN BINDING; STATHMIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897391934     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524014666140228120913     Document Type: Article

References (48)

1. Shi S, Yao W, Xu J, Long J, Liu C, Yu X. Combinational therapy: new hope for pancreatic cancer? Cancer Lett 2012; 317: 127-35.
2. Kramer-Marek G, Gore J, Korc M. Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions. Cancer Lett 2013; 341: 132-8.
3. Xu J, Zhu W, Xu W, et al. Up-regulation of MBD1 promotes pancreatic cancer cell epithelial-mesenchymal transition and invasion by epigenetic down-regulation of E-cadherin. Curr Mol Med 2013; 13: 387-400.
4. Curmi PA, Gavet O, Charbaut E, et al. Stathmin and its phosphoprotein family: general properties, biochemical and functional interaction with tubulin. Cell Struct Funct 1999; 24: 345-57.
5. Jiang L, Chen Y, Chan CY, et al. Down-regulation of stathmin is required for TGF-beta inducible early gene 1 induced growth inhibition of pancreatic cancer cells. Cancer Lett 2009; 274: 101-8.
6. Charbaut E, Curmi PA, Ozon S, Lachkar S, Redeker V, Sobel A. Stathmin family proteins display specific molecular and tubulin binding properties. J Biol Chem 2001; 276: 16146-54.
7. Bloom K. Microtubule cytoskeleton: navigating the intracellular landscape. Curr Biol 2003; 13: R430-2.
8. Vézina A, Vaillancourt-Jean E, Albarao S, Annabi B. Mesenchymal stromal cell ciliogenesis is abrogated in response to tumor necrosis factor-alpha and requires NFkappaB signaling. Cancer Lett 2014; 345: 100-5.
9. Greten FR, Karin M. The IKK/NF-kappaB activation pathwaya target for prevention and treatment of cancer. Cancer Lett 2004; 206: 193-9.
10. Tochinai R, Ando M, Suzuki T, et al. Histopathological studies of microtubule disassembling agent-induced myocardial lesions in rats. Exp Toxicol Pathol 2013; 65: 737-43.
11. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha protein. J Biol Chem 2003; 278: 7445-52.
12. Gavet O, Ozon S, Manceau V, Lawler S, Curmi P, Sobel A. The stathmin phosphoprotein family: intracellular localization and effects on the microtubule network. J Cell Sci 1998; 111 (Pt 22): 3333-46.
13. Peng WX, Pan FY, Liu XJ, et al. Hypoxia stabilizes microtubule networks and decreases tumor cell chemosensitivity to anticancer drugs through Egr-1. Anat Rec (Hoboken) 2010; 293: 414-20.
14. Kang W, Tong JH, Chan AW, et al. Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PLoS One 2012; 7: e33919.
15. Hsieh SY, Huang SF, Yu MC, et al. Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog 2010; 49: 476-87.
16. Jeon TY, Han ME, Lee YW, et al. Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer 2010; 102: 710-8.
17. Mistry SJ, Bank A, Atweh GF. Targeting stathmin in prostate cancer. Mol Cancer Ther 2005; 4: 1821-9.
18. Price DK, Ball JR, Bahrani-Mostafavi Z, et al. The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Invest 2000; 18: 722-30.
19. Yoshie M, Kashima H, Bessho T, Takeichi M, Isaka K, Tamura K. Expression of stathmin, a microtubule regulatory protein, is associated with the migration and differentiation of cultured early trophoblasts. Hum Reprod 2008; 23: 2766-74.
20. Schmitt S, Safferling K, Westphal K, et al. Stathmin regulates keratinocyte proliferation and migration during cutaneous regeneration. PLoS One 2013; 8: e75075.
21. Liu F, Sun YL, Xu Y, Liu F, Wang LS, Zhao XH. Expression and phosphorylation of stathmin correlate with cell migration in esophageal squamous cell carcinoma. Oncol Rep 2013; 29: 419-24.
22. Hsu HP, Li CF, Lee SW, et al. Overexpression of stathmin 1 confers an independent prognostic indicator in nasopharyngeal carcinoma. Tumour Biol 2013; Epub ahead of print.
23. Ke B, Wu LL, Liu N, Zhang RP, Wang CL, Liang H. Overexpression of stathmin 1 is associated with poor prognosis of patients with gastric cancer. Tumour Biol 2013; 34: 3137-45.
24. Ying L, Su D, Zhu J, Ma S, Katsaros D, Yu H. Genotyping of stathmin and its association with clinical factors and survival in patients with ovarian cancer. Oncol Lett 2013; 5: 1315-20.
25. Akhtar J, Wang Z, Jiang WP, Bi MM, Zhang ZP. Stathmin Overexpression Identifies High-Risk of Lymphatic Metastatic Recurrence in pN Esophageal Squamous cell Carcinoma Patients. J Gastroenterol Hepatol 2013; Epub ahead of print.
26. Akhtar J, Wang Z, Yu C, Li CS, Shi YL, Liu HJ. STMN-1 is a potential marker of lymph node metastasis in distal esophageal adenocarcinomas and silencing its expression can reverse malignant phenotype of tumor cells. BMC Cancer 2014; 14: 28.
27. Chen J, Abi-Daoud M, Wang A, et al. Stathmin 1 is a potential novel oncogene in melanoma. Oncogene 2013; 32: 1330-7.
28. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008; 1785: 96-132.
29. Williams K, Ghosh R, Giridhar P V, et al. Inhibition of stathmin1 accelerates the metastatic process. Cancer Res 2012; 72: 5407-17.
30. Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ, George DL. Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 1999; 18: 5954-8.
31. Sonego M, Schiappacassi M, Lovisa S, et al. Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Mol Med 2013; 5: 707-22.
32. Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 2007; 26: 1003-12.
33. Miceli C, Tejada A, Castaneda A, Mistry SJ. Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer. Cancer Gene Ther 2013; 20: 298-307.
34. Carney BK, Caruso Silva V, Cassimeris L. The microtubule cytoskeleton is required for a G2 cell cycle delay in cancer cells lacking stathmin and p53. Cytoskeleton (Hoboken) 2012; 69: 278-89.
35. Wik E, Birkeland E, Trovik J, et al. High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clin Cancer Res 2013; 19: 2331-41.
36. Karst A M, Levanon K, Duraisamy S, et al. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol 2011; 123: 5-12.
37. Feng D, Cao Z, Li C, et al. Combination of valproic acid and ATRA restores RARbeta2 expression and induces differentiation in cervical cancer through the PI3K/Akt pathway. Curr Mol Med 2012; 12: 342-54.
38. Yoshie M, Miyajima E, Kyo S, Tamura K. Stathmin, a microtubule regulatory protein, is associated with hypoxiainducible factor-1alpha levels in human endometrial and endothelial cells. Endocrinology 2009; 150: 2413-8.
39. Bao B, Ali S, Ahmad A, et al. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS One 2012; 7: e50165.
40. Cheng H, Li J, Liu C, et al. Profilin1 sensitizes pancreatic cancer cells to irradiation by inducing apoptosis and reducing autophagy. Curr Mol Med 2013; 13: 1368-75.
41. Schwarzer R, Jundt F. Notch and NF-kappaB signaling pathways in the biology of classical Hodgkin lymphoma. Curr Mol Med 2011; 11: 236-45.
42. Lee KB, Byun HJ, Park SH, Park CY, Lee SH, Rho SB. CYR61 controls p53 and NF-kappaB expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells. Cancer Lett 2012; 315: 86-95.
43. Gocho T, Uwagawa T, Furukawa K, et al. Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-kappaB activation for pancreatic cancer. Cancer Lett 2013; 333: 89-95.
44. Lo SZ, Steer JH, Joyce DA. TNF-alpha renders macrophages resistant to a range of cancer chemotherapeutic agents through NF-kappaB-mediated antagonism of apoptosis signalling. Cancer Lett 2011; 307: 80-92.
45. Liu L, Xu H X, Wang W Q, et al. Cavin-1 is essential for the tumor-promoting effect of caveolin-1 and enhances its prognostic potency in pancreatic cancer. Oncogene 2013; Epub ahead of print.
46. Liu C, Cheng H, Shi S, et al. MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3. Curr Mol Med 2013; 13: 467-78.
47. Moffat J, Grueneberg D A, Yang X, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006; 124: 1283-98.
48. Yao W, Cai X, Liu C, et al. Profilin 1 potentiates apoptosis induced by staurosporine in cancer cells. Curr Mol Med 2013; 13: 417-28.